Escano Crisanto S, Keever Lindsay B, Gutweiler Alexander A, Andresen Bradley T
Internal Medicine/Endocrinology, D109 HSC Diabetes Center, One Hospital Dr., Columbia, MO 65212, USA.
J Pharmacol Exp Ther. 2008 Jan;324(1):34-42. doi: 10.1124/jpet.107.126300. Epub 2007 Oct 2.
Angiotensin II can cause hypertension through enhanced vasoconstriction of renal vasculature. One proposed mechanism for reduction of angiotensin II-induced hypertension is through inhibition of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase cascade. MEK/ERK has been shown to phosphorylate the regulatory subunit of myosin light chain at identical positions as myosin light chain kinase. There are multiple mechanisms proposed regarding angiotensin II-mediated ERK activation. We hypothesized that renal microvascular smooth muscle cells (RmuVSMCs) signal through a unique pathway compared with thoracic aorta smooth muscle cells (TASMCs), which is involved in blood pressure regulation. Use of epidermal growth factor (EGF) and platelet derived growth factor (PDGF) receptor-specific inhibitors 4-(3-chloroanilino)-6,7-dimethoxyquinazoline (AG1478) and 6,7-dimethoxy-3-phenylquinoxaline (AG1296), respectively, demonstrates that angiotensin II activates ERK in TASMCs, but not RmuVSMCs, through transactivation of EGF and PDGF receptors. In addition, inhibition of Src with its specific inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) abolishes angiotensin II-, but not EGF-or PDGF-, mediated phosphorylation of ERK in RmuVSMCs, yet it has no effect in TASMCs. The physiological significance of transactivation was examined in vivo using anesthetized Wistar-Kyoto rats with 15 mg/kg 2'-amino-3'-methoxyflavone (PD98059), an MEK inhibitor, as well as 20 mg/kg AG1478 and 1.5 mg/kg AG1296 in an acute model of angiotensin II-mediated increase in blood pressure. None of the inhibitors had an effect on basal blood pressure, and only PD98059 reduced angiotensin II-mediated increase in blood pressure. Moreover, in RmuVSMCs, but not TASMCs, angiotensin II localizes phosphorylated ERK to actin filaments. In conclusion, angiotensin II signals through a unique mechanism in the renal vascular bed that may contribute to hypertension.
血管紧张素II可通过增强肾血管系统的血管收缩作用导致高血压。一种降低血管紧张素II诱导的高血压的机制是抑制丝裂原活化蛋白激酶激酶(MEK)/细胞外信号调节激酶(ERK)丝裂原活化蛋白激酶级联反应。已证明MEK/ERK可在与肌球蛋白轻链激酶相同的位置使肌球蛋白轻链调节亚基磷酸化。关于血管紧张素II介导的ERK激活有多种机制。我们推测肾微血管平滑肌细胞(RmuVSMC)与胸主动脉平滑肌细胞(TASMC)通过不同的独特信号通路进行信号传导,而该通路参与血压调节。分别使用表皮生长因子(EGF)和血小板衍生生长因子(PDGF)受体特异性抑制剂4-(3-氯苯胺基)-6,7-二甲氧基喹唑啉(AG1478)和6,7-二甲氧基-3-苯基喹喔啉(AG1296),结果表明血管紧张素II通过EGF和PDGF受体的转活化作用激活TASMC中的ERK,但不激活RmuVSMC中的ERK。此外,用其特异性抑制剂4-氨基-5-(4-氯苯基)-7-(叔丁基)吡唑并[3,4-d]嘧啶(PP2)抑制Src可消除血管紧张素II介导的RmuVSMC中ERK的磷酸化,但不影响EGF或PDGF介导的ERK磷酸化,而对TASMC则无影响。在体内,使用15 mg/kg的2'-氨基-3'-甲氧基黄酮(PD98059,一种MEK抑制剂)以及在血管紧张素II介导的血压急性升高模型中使用20 mg/kg AG1478和1.5 mg/kg AG1296,研究了转活化的生理意义。这些抑制剂均对基础血压无影响,只有PD98059能降低血管紧张素II介导的血压升高。此外,在RmuVSMC中,而非TASMC中,血管紧张素II使磷酸化的ERK定位于肌动蛋白丝。总之,血管紧张素II在肾血管床通过独特机制进行信号传导,这可能与高血压的发生有关。